the database
100 peptides
62 carry an established primary sequence. 79 have a PubChem compound record. Fields that are not established read not characterised — they are not filled in with guesses.
100 of 100
| peptide | class | sequence | len | MW | mechanism | status | cites |
|---|---|---|---|---|---|---|---|
| NAD+ nicotinamide adenine dinucleotide |
cofactor | not characterised | — | 663 | Redox coenzyme and substrate for sirtuins and PARPs. | research compound | 8 |
| Acetyl hexapeptide-8 Argireline, acetyl hexapeptide-3 |
cosmetic | EEMQRR | 6 | 887 | SNAP-25 mimetic studied for interference with SNARE complex assembly in vitro. | cosmetic ingredient | 8 |
| Acetyl octapeptide-3 SNAP-8 |
cosmetic | EEMQRRAD | 8 | 1075 | SNAP-25 N-terminal mimetic. | cosmetic ingredient | 2 |
| GHK-Cu copper tripeptide-1 |
cosmetic | GHK | 3 | 401 | Copper-binding tripeptide complex studied for effects on collagen, elastin and antioxidant enzym… | cosmetic ingredient | 8 |
| Palmitoyl pentapeptide-4 Matrixyl, pal-KTTKS |
cosmetic | KTTKS | 5 | 802 | Procollagen fragment reported to signal matrix synthesis in dermal fibroblasts. | cosmetic ingredient | 8 |
| Palmitoyl tetrapeptide-7 | cosmetic | GQPR | 4 | 695 | Studied for effects on interleukin signalling in skin models. | cosmetic ingredient | 4 |
| Palmitoyl tripeptide-1 pal-GHK |
cosmetic | GHK | 3 | 579 | Matrikine-derived signal peptide used in matrix-support formulations. | cosmetic ingredient | 5 |
| CJC-1295 modified GRF (1-29) |
gh-secretagogue | YADAIFTQSYRK… | 29 | 3647 | Growth hormone-releasing hormone analogue acting at GHRH receptors. | research compound | 8 |
| GHRP-2 pralmorelin |
gh-secretagogue | not characterised | — | 818 | Synthetic ghrelin receptor agonist. | research compound | 8 |
| GHRP-6 | gh-secretagogue | not characterised | — | — | Synthetic ghrelin receptor agonist; the first-generation GH-releasing hexapeptide. | research compound | 7 |
| Hexarelin | gh-secretagogue | not characterised | — | 887 | Synthetic GH secretagogue; also studied at CD36 in cardiac tissue. | research compound | 8 |
| IGF-1 LR3 Long R3 IGF-1 |
gh-secretagogue | not characterised | — | — | IGF-1 analogue with reduced IGF-binding-protein affinity. | research compound | 8 |
| Ipamorelin | gh-secretagogue | not characterised | — | 712 | Selective ghrelin receptor (GHS-R1a) agonist; described as releasing GH with minimal effect on c… | research compound | 8 |
| MGF mechano growth factor, IGF-1Ec |
gh-secretagogue | not characterised | — | — | Splice variant of IGF-1 expressed after mechanical loading; the E-domain peptide is the studied … | preclinical | 7 |
| Sermorelin GRF (1-29) |
gh-secretagogue | YADAIFTNSYRK… | 29 | 3358 | The N-terminal 29 residues of GHRH — the shortest fully active fragment. | approved | 8 |
| Tesamorelin Egrifta |
gh-secretagogue | not characterised | — | 5136 | GHRH analogue; approved for HIV-associated lipodystrophy. | approved | 8 |
| BPC-157 Body Protection Compound 157, pentadecapeptide BPC 157 |
healing | GEPPPGKPADDA… | 15 | 1420 | Pentadecapeptide derived from a gastric juice protein sequence; studied for effects on angiogene… | preclinical | 8 |
| GHK glycyl-histidyl-lysine |
healing | GHK | 3 | 340 | Matrix-derived tripeptide with high copper(II) affinity; described as a signal generated on tiss… | research compound | 8 |
| Larazotide AT-1001 |
healing | GGVLVQPG | 8 | 726 | Tight-junction regulator studied as a zonulin antagonist in intestinal permeability. | in clinical study | 3 |
| TB-500 thymosin β4 fragment (17-23) |
healing | LKKTETQ | 7 | 889 | Actin-binding fragment of thymosin β4; the LKKTETQ motif is the actin-binding region described i… | preclinical | 8 |
| Thymosin β4 Tβ4, TMSB4X |
healing | SDKPDMAEIEKF… | 43 | 4921 | G-actin sequestering protein; studied in wound repair, corneal healing and cardiac injury models… | in clinical study | 8 |
| Abaloparatide Tymlos |
hormone | not characterised | — | 3961 | PTH1R agonist selective for the RG conformation. | approved | 8 |
| Angiotensin II | hormone | DRVYIHPF | 8 | 1046 | AT1/AT2 receptor agonist; the effector peptide of the renin-angiotensin system. | approved | 8 |
| Atrial natriuretic peptide ANP, atrial natriuretic factor |
hormone | SLRRSSCFGGRM… | 28 | 3081 | NPR-A agonist; raises cGMP, promoting natriuresis and vasodilation. | research compound | 8 |
| Bombesin | hormone | not characterised | — | 1620 | Binds mammalian bombesin-family receptors (GRPR/NMBR); a frog-skin peptide widely used as a rese… | research compound | 8 |
| Bradykinin | hormone | RPPGFSPFR | 9 | 1060 | B2 receptor agonist; mediator of vasodilation and pain signalling. | research compound | 8 |
| Calcitonin (salmon) salmon calcitonin, calcitonin |
hormone | CSNLSTCVLGKL… | 32 | 3432 | Calcitonin receptor agonist; inhibits osteoclast activity. | approved | 8 |
| Cetrorelix | hormone | not characterised | — | 1431 | Competitive GnRH receptor antagonist; suppresses LH without an initial flare. | approved | 8 |
| Desmopressin DDAVP |
hormone | not characterised | — | 1069 | Selective V2 receptor agonist with minimal vasopressor activity. | approved | 8 |
| Dynorphin A (1-13) | hormone | YGGFLRRIRPKL… | 13 | 1604 | Kappa-opioid receptor agonist. | research compound | 5 |
| Galanin | hormone | GWTLNSAGYLLG… | 30 | 3157 | GAL1-3 receptor agonist; neuropeptide with roles in mood, feeding and nociception. | research compound | 8 |
| Ghrelin | hormone | GSSFLSPEHQRV… | 28 | 3245 | Endogenous GHS-R1a agonist; the hunger hormone. | research compound | 8 |
| Glucagon | hormone | HSQGTFTSDYSK… | 29 | 3483 | Glucagon receptor agonist; raises hepatic glucose output. | approved | 8 |
| Gonadorelin GnRH, LHRH |
hormone | not characterised | — | 1182 | GnRH receptor agonist driving LH and FSH release. | approved | 8 |
| Icatibant Firazyr |
hormone | not characterised | — | 1305 | Selective bradykinin B2 receptor antagonist. | approved | 8 |
| Insulin | hormone | not characterised | — | 5794 | Insulin receptor agonist. | approved | 8 |
| Kisspeptin-10 | hormone | YNWNSFGLRF | 10 | 1302 | KISS1R agonist upstream of GnRH release. | in clinical study | 8 |
| Leu-enkephalin | hormone | YGGFL | 5 | 556 | Endogenous opioid pentapeptide differing from Met-enkephalin at the C-terminal residue. | research compound | 7 |
| Leuprolide leuprorelin, Lupron |
hormone | not characterised | — | 1209 | GnRH receptor agonist; continuous exposure downregulates the receptor and suppresses gonadotropi… | approved | 8 |
| Met-enkephalin opioid growth factor |
hormone | YGGFM | 5 | 574 | Endogenous opioid pentapeptide; delta-opioid receptor preferring. | research compound | 8 |
| Nesiritide BNP, B-type natriuretic peptide |
hormone | SPKMVQGSGCFG… | 32 | 3464 | NPR-A agonist; recombinant human B-type natriuretic peptide. | approved | 8 |
| Neuropeptide Y NPY |
hormone | YPSKPDNPGEDA… | 36 | 4254 | Y1-Y5 receptor agonist; one of the most abundant neuropeptides in the brain. | research compound | 8 |
| Neurotensin | hormone | not characterised | — | 1673 | NTSR1/NTSR2 agonist; neuromodulator with roles in dopamine signalling and thermoregulation. | research compound | 8 |
| Octreotide Sandostatin |
hormone | not characterised | — | 1019 | Somatostatin analogue with SSTR2/SSTR5 selectivity. | approved | 8 |
| Orexin-A hypocretin-1 |
hormone | not characterised | — | 3561 | OX1R/OX2R agonist; central regulator of arousal and wakefulness. | research compound | 7 |
| Oxytocin | hormone | CYIQNCPLG | 9 | 1007 | Oxytocin receptor agonist; neurohypophysial nonapeptide. | approved | 8 |
| Somatostatin-14 | hormone | AGCKNFFWKTFT… | 14 | 1638 | Pan-somatostatin receptor agonist; broad inhibitor of endocrine secretion. | research compound | 7 |
| Substance P | hormone | RPKPQQFFGLM | 11 | 1348 | Tachykinin NK1 receptor agonist; a principal nociceptive and inflammatory neuropeptide. | research compound | 8 |
| Teriparatide PTH (1-34), Forteo |
hormone | SVSEIQLMHNLG… | 34 | 4118 | PTH1R agonist; intermittent exposure drives bone formation. | approved | 8 |
| TRH thyrotropin-releasing hormone, protirelin |
hormone | not characterised | — | 362 | TRH receptor agonist driving TSH and prolactin release. | approved | 8 |
| Vasopressin ADH, antidiuretic hormone |
hormone | CYFQNCPRG | 9 | 1087 | V1/V2 receptor agonist regulating water retention and vascular tone. | approved | 8 |
| VIP vasoactive intestinal peptide |
hormone | HSDAVFTDNYTR… | 28 | 3327 | VPAC1/VPAC2 receptor agonist; vasodilator and immunomodulator. | research compound | 8 |
| Ziconotide Prialt, ω-conotoxin MVIIA |
hormone | not characterised | — | 2639 | Selective N-type (Cav2.2) calcium channel blocker. | approved | 7 |
| Daptomycin Cubicin |
immune | not characterised | — | 1621 | Calcium-dependent insertion into Gram-positive membranes, causing depolarisation. | approved | 8 |
| Enfuvirtide T-20, Fuzeon |
immune | YTSLIHSLIEES… | 36 | 4492 | HIV-1 fusion inhibitor; binds gp41 and blocks the conformational change required for membrane fu… | approved | 7 |
| Human β-defensin 2 hBD-2, DEFB4A |
immune | GIGDPVTCLKSG… | 41 | 4334 | Inducible epithelial antimicrobial peptide; also a CCR6 chemoattractant. | preclinical | 8 |
| KPV α-MSH (11-13), KPV tripeptide |
immune | KPV | 3 | 342 | C-terminal tripeptide of α-MSH; studied for anti-inflammatory activity independent of pigmentati… | preclinical | 8 |
| LL-37 cathelicidin antimicrobial peptide |
immune | LLGDFFRKSKEK… | 37 | 4493 | Human cathelicidin-derived antimicrobial peptide; forms an amphipathic helix that disrupts micro… | preclinical | 8 |
| Magainin 2 | immune | GIGKFLHSAKKF… | 23 | 2467 | Amphipathic antimicrobial peptide from frog skin; permeabilises microbial membranes. | preclinical | 8 |
| Melittin | immune | GIGAVLKVLTTG… | 26 | 2847 | Amphipathic membrane-lytic peptide from honeybee venom; a standard model of pore formation. | preclinical | 8 |
| Polymyxin B | immune | not characterised | — | — | Binds lipid A in the Gram-negative outer membrane and disrupts it. | approved | 8 |
| Thymosin α1 thymalfasin, Zadaxin |
immune | SDAAVDTSSEIT… | 29 | 3108 | Thymic peptide studied as a TLR-pathway immunomodulator; used clinically in several countries. | approved | 8 |
| Thymulin | immune | QAKSQGGSN | 9 | 876 | Zinc-dependent thymic hormone studied in T-cell differentiation. | preclinical | 8 |
| Tuftsin | immune | TKPR | 4 | 501 | Immunostimulatory tetrapeptide derived from the IgG heavy-chain Fc region. | preclinical | 8 |
| Vancomycin | immune | not characterised | — | 1449 | Binds the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking cell-wall cross-linking. | approved | 8 |
| Exenatide Byetta, exendin-4 |
incretin | HGEGTFTSDLSK… | 39 | 4187 | GLP-1 receptor agonist resistant to DPP-4 cleavage. | approved | 8 |
| GIP glucose-dependent insulinotropic polypeptide |
incretin | YAEGTFISDYSI… | 42 | 4984 | Incretin hormone acting at the GIP receptor. | research compound | 8 |
| GLP-1 (7-37) glucagon-like peptide-1 |
incretin | HAEGTFTSDVSS… | 31 | 3356 | Endogenous incretin; potentiates glucose-dependent insulin secretion. | research compound | 8 |
| Liraglutide Victoza, Saxenda |
incretin | HAEGTFTSDVSS… | 31 | 3751 | GLP-1 receptor agonist with fatty-acid acylation for albumin binding. | approved | 8 |
| Retatrutide LY3437943 |
incretin | not characterised | — | — | Triple agonist at GIP, GLP-1 and glucagon receptors. | in clinical study | 8 |
| Semaglutide Ozempic, Wegovy |
incretin | HAEGTFTSDVSS… | 31 | 4114 | GLP-1 receptor agonist; the acyl chain drives albumin binding and extends circulating half-life. | approved | 8 |
| Survodutide BI 456906 |
incretin | not characterised | — | 4232 | Dual agonist at the glucagon and GLP-1 receptors. | in clinical study | 8 |
| Tirzepatide Mounjaro, Zepbound |
incretin | not characterised | — | 4813 | Dual GIP and GLP-1 receptor agonist. | approved | 8 |
| Carnosine | longevity | not characterised | — | 226 | Endogenous dipeptide studied as a pH buffer and carbonyl scavenger in muscle. | research compound | 8 |
| Epitalon epithalon, AEDG |
longevity | AEDG | 4 | 390 | Tetrapeptide from the Khavinson series, studied in relation to telomerase activity and pineal fu… | preclinical | 8 |
| Glutathione GSH |
longevity | not characterised | — | 307 | Principal intracellular thiol antioxidant and cofactor for glutathione peroxidases. | research compound | 8 |
| Pinealon EDR peptide |
longevity | EDR | 3 | 418 | Short regulatory peptide from the Khavinson series studied in neuronal models. | preclinical | 8 |
| Vilon Lys-Glu, KE peptide |
longevity | KE | 2 | 275 | Short regulatory dipeptide from the Khavinson peptide series, studied for immune and gene-expres… | preclinical | 8 |
| Afamelanotide Melanotan I, NDP-α-MSH |
melanocortin | not characterised | — | 1647 | MC1R agonist; approved for erythropoietic protoporphyria. | approved | 8 |
| Bremelanotide PT-141, Vyleesi |
melanocortin | not characterised | — | 1025 | Melanocortin receptor agonist acting centrally, with MC4R implicated. | approved | 8 |
| Melanotan II | melanocortin | not characterised | — | 1024 | Non-selective melanocortin receptor agonist. | research compound | 8 |
| Setmelanotide Imcivree |
melanocortin | not characterised | — | 1117 | MC4R agonist. | approved | 8 |
| α-MSH alpha-melanocyte stimulating hormone |
melanocortin | SYSMEHFRWGKP… | 13 | 1665 | Endogenous melanocortin agonist; the parent of the MT-I/MT-II analogue family. | research compound | 8 |
| AOD-9604 hGH fragment 177-191 analogue |
metabolic | YLRIVQCRSVEG… | 16 | 1815 | Growth-hormone C-terminal fragment studied for lipolytic activity without the full GH receptor p… | research compound | 8 |
| Cagrilintide | metabolic | not characterised | — | 4409 | Amylin receptor agonist, studied in combination with GLP-1 agonists. | in clinical study | 8 |
| GLP-2 glucagon-like peptide-2 |
metabolic | HADGSFSDEMNT… | 33 | 3766 | GLP-2 receptor agonist; trophic to intestinal mucosa. | research compound | 8 |
| HGH Fragment 176-191 | metabolic | LRIVQCRSVEGS… | 15 | 1654 | C-terminal GH fragment investigated for effects on adipose tissue. | research compound | 2 |
| Leptin fragment (116-130) | metabolic | not characterised | — | — | Fragment of leptin investigated for metabolic signalling; primary structure varies by construct … | preclinical | 6 |
| Linaclotide Linzess |
metabolic | CCEYCCNPACTG… | 14 | 1527 | Guanylate cyclase-C agonist acting locally in the intestinal lumen. | approved | 8 |
| Pramlintide Symlin, amylin analogue |
metabolic | KCNTATCATQRL… | 37 | 3949 | Amylin analogue acting at amylin/calcitonin receptor complexes. | approved | 8 |
| Teduglutide GLP-2 analogue, Gattex |
metabolic | HGDGSFSDEMNT… | 33 | 3752 | GLP-2 receptor agonist; Gly2 substitution confers DPP-4 resistance. | approved | 8 |
| Humanin | mitochondrial | MAPRGFSCLLLL… | 24 | 2687 | Mitochondrial-derived peptide studied for cytoprotective signalling. | preclinical | 8 |
| MOTS-c | mitochondrial | MRWQEMGYIFYP… | 16 | 2175 | Mitochondrial-derived peptide encoded in the 12S rRNA region; described as acting through AMPK a… | preclinical | 8 |
| SS-31 elamipretide, MTP-131 |
mitochondrial | not characterised | — | 640 | Cardiolipin-binding tetrapeptide studied for mitochondrial inner-membrane stabilisation. | in clinical study | 8 |
| Cerebrolysin | nootropic | not characterised | — | — | Peptide preparation studied for neurotrophic-like activity. | in clinical study | 8 |
| Cortagen AEDP peptide |
nootropic | AEDP | 4 | 430 | Khavinson-series tetrapeptide studied in peripheral nerve models. | preclinical | 5 |
| Dihexa N-hexanoic-Tyr-Ile-(6) aminohexanoic amide |
nootropic | not characterised | — | 505 | Angiotensin IV analogue studied as an HGF/c-Met potentiator in neural models. | preclinical | 8 |
| DSIP delta sleep-inducing peptide |
nootropic | WAGGDASGE | 9 | 849 | Nonapeptide originally isolated from rabbit cerebral venous blood during induced sleep; mechanis… | preclinical | 8 |
| Selank | nootropic | TKPRPGP | 7 | 752 | Tuftsin analogue (Thr-Lys-Pro-Arg) extended with Pro-Gly-Pro; studied for anxiolytic-like activi… | preclinical | 8 |
| Semax | nootropic | MEHFPGP | 7 | 814 | ACTH(4-7) analogue extended with Pro-Gly-Pro; studied in relation to BDNF expression in animal m… | preclinical | 8 |
- hydrophobic
- positive
- negative
- polar
- aromatic
- glycine
- proline
- cysteine